风湿疾病药物在 COVID-19 中的保护作用。
The protective effect of rheumatic disease agents in COVID-19.
机构信息
Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA.
出版信息
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101659. doi: 10.1016/j.berh.2021.101659. Epub 2021 Jan 13.
Abstract
Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.
摘要
几种免疫抑制疗法已被研究作为严重和危重新冠病毒病 2019（COVID-19）患者的潜在治疗方法。值得注意的例子包括皮质类固醇、白细胞介素 6（IL-6）、白细胞介素 1（IL-1）、Janus 激酶（JAK）和肿瘤坏死因子-α（TNF-α）抑制剂。本叙述性综述的目的是分析这些选定的抗风湿药物治疗 COVID-19 的机制合理性和现有证据。目前，只有皮质类固醇已被证明能有效降低死亡率，并在治疗严重和危重新冠病毒病的临床指南中推荐使用。多项随机对照试验（RCT）正在进行中，以确定其他免疫抑制剂的作用。
相似文献
1
The protective effect of rheumatic disease agents in COVID-19.风湿疾病药物在 COVID-19 中的保护作用。
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101659. doi: 10.1016/j.berh.2021.101659. Epub 2021 Jan 13.
2
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 疫情期间的风湿性疾病生物制剂：是敌是友？
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.
3
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.抗风湿药物的抗病毒作用：COVID-19 带来的启示。
J Autoimmun. 2020 Jul;111:102468. doi: 10.1016/j.jaut.2020.102468. Epub 2020 Apr 17.
4
Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.生物制剂类疾病修饰抗风湿药物和 Janus 激酶抑制剂在儿科风湿病学中的应用——来自随机对照试验的我们所知和未知。
Pediatr Rheumatol Online J. 2021 Mar 25;19(1):46. doi: 10.1186/s12969-021-00514-4.
5
Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.白细胞介素-1 抑制剂和疫苗接种（包括 COVID-19）在炎症性风湿病中的应用：一项非系统性综述。
Front Immunol. 2022 Jan 27;12:734279. doi: 10.3389/fimmu.2021.734279. eCollection 2021.
6
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.生物制剂治疗的风湿性疾病合并冠状病毒感染的推荐建议。
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
7
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
8
Managing rheumatic diseases during COVID-19.COVID-19 期间风湿性疾病的管理。
Clin Rheumatol. 2020 Nov;39(11):3245-3254. doi: 10.1007/s10067-020-05387-8. Epub 2020 Sep 8.
9
COVID-19 in rheumatic disease patients on immunosuppressive agents.COVID-19 与免疫抑制剂治疗的风湿性疾病患者。
Semin Arthritis Rheum. 2020 Aug;50(4):680-686. doi: 10.1016/j.semarthrit.2020.05.010. Epub 2020 May 23.
10
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.COVID-19 疫苗接种在自身免疫性炎症性风湿病患者中的应用：韩国风湿病学会的临床指南。
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.
引用本文的文献
1
Cardioprotective effects of vaccination in hospitalized patients with COVID-19.COVID-19 住院患者疫苗接种的心脏保护作用。
Clin Exp Med. 2024 May 17;24(1):103. doi: 10.1007/s10238-024-01367-3.
2
Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system.机器学习理解 COVID-19 重症结局的风险：一项回顾性队列研究，研究对象为美国大型医疗保健系统中的免疫介导的炎症性疾病、免疫调节药物和合并症。
Lancet Digit Health. 2024 May;6(5):e309-e322. doi: 10.1016/S2589-7500(24)00021-9.
3
Druggable targets and therapeutic development for COVID-19.2019冠状病毒病的可药物化靶点与治疗开发
Front Chem. 2022 Oct 5;10:963701. doi: 10.3389/fchem.2022.963701. eCollection 2022.
4
Current challenges in different approaches to control COVID-19: a comprehensive review.控制新冠病毒的不同方法中的当前挑战：一项全面综述
Bull Natl Res Cent. 2022;46(1):47. doi: 10.1186/s42269-022-00730-2. Epub 2022 Mar 3.
5
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.靶向治疗在 COVID-19 结局中的风湿患者中的作用：COVIDSER 研究结果。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001925.
6
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?比较 COVID-19、H1N1 流感、CRS 和 MAS 的细胞因子风暴。一种治疗方法能适用于所有情况吗？
Cytokine. 2021 Aug;144:155593. doi: 10.1016/j.cyto.2021.155593. Epub 2021 May 26.
本文引用的文献
1
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.阿那白滞素作为治疗对托珠单抗难治的 SARS-CoV-2 相关严重急性呼吸道感染的一种潜在替代药物。
Reumatol Clin (Engl Ed). 2021 Dec;17(10):559-561. doi: 10.1016/j.reumae.2020.06.008. Epub 2020 Oct 15.
2
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.JAK 抑制剂和 I 型干扰素在 COVID-19 患者中产生良好临床结局的能力：系统评价和荟萃分析。
BMC Infect Dis. 2021 Jan 11;21(1):47. doi: 10.1186/s12879-020-05730-z.
3
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
4
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
5
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
6
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.COVID-19 重症患者中氢化可的松对 21 天死亡率或呼吸支持的影响：一项随机临床试验。
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
7
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者：一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
8
Canakinumab in a subgroup of patients with COVID-19.卡那单抗用于新冠肺炎患者亚组。
Lancet Rheumatol. 2020 Aug;2(8):e457-ee458. doi: 10.1016/S2665-9913(20)30167-3. Epub 2020 Jun 4.
9
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
10
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.抗风湿疾病疗法治疗 COVID-19：系统评价和荟萃分析。
Arthritis Rheumatol. 2021 Jan;73(1):36-47. doi: 10.1002/art.41469. Epub 2020 Nov 19.
Zotero 插件